Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
· Financial Post
“This acquisition reinforces our commitment to delivering transformative solutions for patients with significant unmet needs,” said Christelle Huguet, PhD, EVP, Head of R&D, Ipsen. “With potravitug, we have the opportunity to add a promising first-in-class asset to our rare disease pipeline and address the significant clinical consequences of BK virus–associated nephropathy in kidney transplant recipients, where current standards of care can compromise transplant success and graft outcomes.” Read More
Visit saltysenoritaaz.org for more information.